Revenue
2023
2024
2025
2026
BetterLife Pharma Inc. (BETRF)
Price$0.2216Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2019
2020
2021
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $85,672 | $424,337 | $570,947 | $2.7M | $5.4M | $284,700 | $63,767 | $430,456 | $90,826 | — | — | — | — | — | — | — | — | — |
| Operating expenses | $1.8M | $5.0M | $3.2M | $9.5M | $10.2M | $7.9M | $9.3M | $6.8M | $1.4M | — | — | $130,810 | $76,887 | $88,893 | — | — | — | — |
| Operating income | −$1.8M | −$5.0M | −$3.2M | −$9.5M | — | — | — | −$6.8M | −$1.4M | — | — | — | — | — | — | — | — | — |
| EBITDA | −$1.3M | −$5.0M | −$3.2M | −$9.4M | — | — | — | −$5.9M | −$1.3M | — | — | — | — | — | — | — | — | — |
| Net income | −$1.5M | −$3.6M | −$2.9M | −$9.4M | −$12.2M | −$36.4M | −$19.6M | −$9.1M | −$42,354 | — | — | −$1.3M | −$753,875 | $341,425 | $1.4M | −$3.0M | −$120,134 | −$653,761 |
| Basic EPSper basic share | -CA$0.01 | -CA$0.03 | -CA$0.03 | -CA$0.10 | — | -CA$1.34 | -CA$1.30 | -CA$0.10 | CA$0.00 | — | — | -CA$0.11 | -CA$0.20 | — | — | — | — | — |
| Diluted EPSper diluted share | -CA$0.01 | -CA$0.03 | -CA$0.03 | -CA$0.10 | -CA$0.16 | -CA$1.34 | -CA$1.30 | -CA$0.10 | CA$0.00 | — | — | -CA$0.11 | -CA$0.20 | — | — | — | — | — |
Owners
Reported shareholders